Xiangmin Lv, Chunbo He, Cong Huang, Hongbo Wang, Guohua Hua, Zhengfeng Wang, Jin Zhou, Xingcheng Chen, Bowen Ma, Barbara K. Timm, Victoria Maclin, Jixin Dong, Bo R. Rueda, John S. Davis, Cheng Wang
7 min
This study investigates the role of the Hippo signaling pathway, specifically the effector protein YAP1, in the development of ovarian follicles. While the Hippo pathway is a well-known regulator of organ size and cell fate in other tissues, its specific function in the proliferation and differentiation of granulosa cells—the somatic cells essential for oocyte maturation and hormone production—remained poorly understood.
The researchers examined the spatiotemporal expression of YAP1 in human and mouse ovarian tissues using immunohistochemistry. To determine its functional role, they employed both in vitro pharmacological inhibition (using verteporfin) and in vivo genetic approaches. Specifically, they generated conditional knockout mouse models using the Foxl2 promoter (to target granulosa cells) and the Cyp19a1 promoter (to target differentiated granulosa and luteal cells) to observe the effects of YAP1 loss on ovarian morphology, follicle development, and fertility.
The study reveals that YAP1 activity is tightly regulated during follicle development. In proliferative granulosa cells, YAP1 is localized to the nucleus, where it drives cell proliferation and survival. Conversely, in terminally differentiated luteal cells, YAP1 is sequestered in the cytoplasm, rendering it inactive. Pharmacological inhibition or genetic deletion of YAP1 in granulosa cells led to increased apoptosis, reduced ovarian size, and significant subfertility. Mechanistically, YAP1 was found to interact with the EGFR and TGF-beta signaling pathways to coordinate the balance between granulosa cell proliferation and differentiation.
These findings identify YAP1 as a central orchestrator of ovarian function. By demonstrating that the timely activation and subsequent inactivation of YAP1 are required for successful follicle development, the study provides a potential therapeutic target for treating subfertility linked to abnormal granulosa cell function or premature ovarian failure.
Alex: That's the key question, and they addressed it directly. First, they deleted the YAP1 gene entirely in granulosa cells. Without it, the cells couldn't multiply properly, and the follicles failed to develop. Then they used a drug called Verteporfin, which blocks YAP1 from functioning—and saw the same result. Disrupted growth, disrupted maturation.
Sam: So removing the foreman, or just handcuffing them, both stall the project.
Alex: That's a fair summary. And there's another layer to this. It's not just a one-way instruction. The researchers found that YAP1 also boosts the production of certain growth-promoting molecules—one in particular called HBEGF—which in turn keeps YAP1 active in the nucleus. So it's a feedback loop: YAP1 promotes its own continued activity, keeping the cell locked in growth mode until an external signal finally breaks the cycle and triggers the move to the cytoplasm.
Sam: That makes the timing feel quite delicate. If the loop is too strong, the cell never gets the signal to mature?
Alex: Precisely. They demonstrated this using a three-dimensional cell culture system—essentially growing cells in a gel scaffold that mimics the physical environment inside the body, rather than a flat dish. When they gave cells extra YAP1 in that environment, the cells formed larger clusters, confirming they were dividing more. But those same cells produced fewer hormones. Too much foreman activity, and the crew never finishes the building.
Sam: So the balance matters as much as the signal itself.
Alex: That's the core finding. It's not simply that YAP1 is good or bad—it's that the right amount, in the right place, at the right time, is what allows the follicle to develop normally.
Sam: Given that a lot of this work used mouse models, how much confidence should we have that it applies to humans?
Alex: The paper is measured on that point. The researchers did examine human tissue and found the same pattern—YAP1 in the nucleus during growth, in the cytoplasm at maturity. But they're careful to note that we don't yet know how effective it would be to target this pathway therapeutically in humans. The findings are a meaningful step toward understanding the mechanism, but clinical applications would require considerably more research.
Sam: So this is more about building the foundation than offering an immediate treatment?
Alex: That's a reasonable way to put it. Understanding the molecular logic of how follicles transition from growth to maturity gives researchers a clearer target for future work—particularly in cases where granulosa cell function is abnormal and follicles fail to develop properly. Whether that eventually translates into a treatment is a question for future studies to answer.
Sam: It's a good reminder of how much complexity is packed into what looks like a straightforward biological process.
Alex: It really is. A single protein, moving between two compartments of a cell, coordinating an entire developmental transition. The simplicity of the mechanism is what makes it worth paying attention to. Thanks for listening to ResearchPod.